Dermoscopy complements the initial skin examination by providing a more structured assessment of lesion features. It helps clinicians decide which growths require tissue confirmation when visual findings raise concern. This tool supports clinical judgment before histopathology, but it does not replace microscopic examination when malignancy remains suspected.
Histopathological analysis provides diagnostic confirmation that surface examination cannot supply. Microscopic review of the tissue can identify whether the growth is benign, precancerous, or malignant and can establish the tumor type. It also documents features such as depth, giving clinicians evidence for classification and subsequent treatment decisions.
Molecular testing adds another layer of characterization for selected tumors rather than serving as a universal first step. Used alongside clinical and microscopic assessment, it may provide information about tumor characteristics that supports classification. In cancer research, this information also contributes to the development of targeted therapies for appropriate tumor groups.
Accurate classification requires more than recognizing an abnormal growth. Separating melanoma from nonmelanoma skin cancers establishes a clinically meaningful tumor category, while recording depth and spread adds information about disease status. Together, these findings support prognosis, meaning an estimate of expected disease behavior, and enable more consistent comparison among research cases.
The workflow begins with visual examination and dermoscopy of the lesion. If the findings warrant further evaluation, clinicians remove a tissue sample for microscopic histopathological analysis. Molecular testing may then be added for selected tumors to provide further characterization. This sequence combines initial lesion assessment with tissue-based confirmation and optional molecular information.
In cancer research, diagnostic findings generate standardized information about tumor type, depth, and spread. Investigators can use these data to classify cases, examine prognosis, and evaluate patterns relevant to early detection. The same framework supports development of improved screening approaches and targeted therapies based on characteristics identified in selected tumors.